ABSTRACT
Objective Compare and analyze the serum proteomics data of healthy human and patients with bronchial asthma(both before and after ICS treatment).Then explore the possible pathogenesis and therapeutic targets.MethodsSelect 102 patients with chronic persistent asthma who were diagnosed and treated in our hospital during December 2015 to December 2016, and recruit 102 cases of healthy volunteers over the same period.The patients were treated with conventional ICS, after 8 weeks of treatment, compare and analyzethe serum proteomics data of healthy people and both patients with bronchial asthma (both before and after treatment).ResultsAfter treatment, patients with asthma still got poorer lung function than normal ones (P<0.05);at the same time, all of the serum HSP70, Eotaxin, MMP-9 of pre-treatment patients were higher than healthy individuals (P<0.05), although they had declined after treatment (P<0.05), but still higher than normal people(P<0.05).ConclusionHuman serum HSP70, Eotaxin, MMP-9 may not only be involved in the pathogenesis progress of asthma, but the mechanisms of treating asthma with ICS.